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StabilityAbstract Sildenaﬁl citrate was crystallized by various techniques aiming to determine the behavior
and factors affecting the crystal growth. There are only 2 types of sildenaﬁl obtaining from crystal-
lization: sildenaﬁl (1) and sildenaﬁl citrate monohydrate (2). The used techniques were (i) crystalli-
zation from saturated solutions, (ii) addition of an antisolvent, (iii) reﬂux and (iv) slow solvent
evaporation method. By pursuing these various methods, our work pointed that the best formation
of crystal (1) was obtained from technique no. (i). Surprisingly, the obtained crystals (1) were per-
fected if the process was an acidic pH at a cold temperature then perfect crystals occurred within a
day. Crystals of compound (2) grew easily using technique no. (ii) which are various polar solvents
over a wide range of pH and temperature preparation processes. The infrared spectroscopy and
Sildenaﬁl and sildenaﬁl citrate monohydrate crystals 505nuclear magnetic resonance spectra ﬁt well with these two X-ray crystal structures. The crystal
structures of sildenaﬁl free base and salt forms were different from their different growing condi-
tions leading to stability difference.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Figure 1 Chemical structures of sildenaﬁl (1) and sildenaﬁl
citrate monohydrate (2).1. Introduction
The crystal structures of drug compounds or proteins acting as
receptors in human physiological processes have been of inter-
est in order to obtain a better understanding of molecular
structure and drug-receptor interactions (Zhang et al., 2012;
Datta and Grant, 2004). Generally, the searching and improv-
ing methodology for those compounds are continuously under
investigation. Traditionally, the crystal structure of drugs can
be determined from a single crystal X-ray diffraction tech-
nique, which is the most straightforward tool for elucidating
crystal and molecular structures. However, it is difﬁcult and
time consuming to prepare single crystals of drugs and the
crystals are easily dehydrated (Guo et al., 2011).
The discovery of sildenaﬁl began by the efforts of Nobel
Prize winners Furchgott, Ignarro and Murad who also had dis-
covered the link between nitric oxide (NO) and the human car-
diovascular system. These research workers took this ﬁnding
and developed a new ring system hoping to produce new drugs
that would potentiate the effects of NO on the cardiovascular
system such as UK-92-480, later known as sildenaﬁl. This mol-
ecule was synthesized for the purpose of modifying NO pro-
duction not only for a clinical study but also for its launch
in the market after the US FDA approved it on 27 March
1998 (McCullough, 2002). Sildenaﬁl and its derivatives or salts
are highly potent pharmaceutical drugs that selectively inhibi-
tor of cyclic guanosine monophosphate (cGMP) and are spe-
ciﬁc as a phosphodiesterase-5 (PDE-5) inhibitor. By
inhibiting the hydrolytic breakdown of cGMP, sildenaﬁl pro-
longs the action of cGMP. This results in augmented
smooth-muscle relaxation (Raja et al., 2006; Nichols et al.,
2002). Sildenaﬁl was also the ﬁrst oral agent used for the med-
ical treatment of erectile dysfunction and has been
subsequently shown to have important effects on the pulmon-
ary vasculature and because of that has been recently used for
the treatment of pulmonary hypertension (PH) (Chockalingam
et al., 2005; Nichols et al., 2002; Galie` et al., 2009). Due to low
water solubility of sildenaﬁl, the manufacturer improved its
water solubility by salt formation as sildenaﬁl citrate.
The molecular structures of sildenaﬁl (C22H30N6O4S) (1)
known chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-pro-
pyl-1H-pyrazolo [4, 3-d] pyrimidin-5-yl)-4-ethoxyphenyl] sul-
fonyl]-4-methylpiperazine. Sildenaﬁl citrate and sildenaﬁl
citrate monohydrate (C28H40N6O12S) (2) are shown in Fig 1
(Al-Omari et al., 2006).
From the literature, there have been previous reports on the
crystallization techniques used for sildenaﬁl (Stepanovs and
Mishnev, 2012), its citrate salt (Yathirajan et al., 2005) and
saccharinate salt (Banergee et al., 2006). The basic sildenaﬁl
crystal was prepared from sildenaﬁl citrate by reaction with
a stoichiometric amount of aqueous KOH solution. The citrate
salt was then separated from the sildenaﬁl molecule. The
crystal is a monoclinic system, with the space group P21/cand unit cell parameters of a= 17.273(1), b= 17.0710(8),
c= 8.3171 (4) A˚, b= 99.326(2), Z= 4, V= 2420.0(3) A˚3
(Stepanovs and Mishnev, 2012). Sildenaﬁl citrate monohydrate
was prepared by recrystallization from dimethylformamide.
The crystal was orthorhombic with the space group Pbca
and unit cell parameters of a= 24.002(4), b= 10.9833(17),
c= 24.363(3) A˚, Z= 8, V= 6422.9(17) A˚3 (Yathirajan
et al., 2005). In addition, sildenaﬁl saccharinate was prepared
by grinding 1:1 M proportions of dry sildenaﬁl and saccharin.
The crystal of sildenaﬁl saccharinate was triclinic, with space
group P1 and unit cell parameters of a= 10.3848(10),
b= 11.1915(11), c= 14.3155(14) A˚, Z= 2, V= 1546.5(3)
A˚3 (Banergee et al., 2006). Sildenaﬁl had a pKa1 value of
9.84 at its amide (pyrimidine ring) and a pKa2 value of 7.10
at its tertiary amine (piperazine ring) (Al-Omari et al., 2006).
The solubility of sildenaﬁl depends on pH of solvent and its
pKa which affects the crystal growth of sildenaﬁl. In addition,
the co-crystals of sildenaﬁl with co-former agent were reported
(Sanphui et al., 2013; Zegarac et al., 2007). The crystals of sil-
denaﬁl and sildenaﬁl citrate monohydrate reported in the liter-
atures (Stepanovs and Mishnev, 2012; Yathirajan et al., 2005)
were unstable as the R value was still high. Hence this study
aimed to prepare sildenaﬁl crystal and analyze crystallization
data together with molecular interaction.
We hope to understand the crystal growth behavior and
optimize the quality of single crystals. Growth from solution
Figure 2 Schematic diagram of different crystallization methods.
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production of single crystals for basic and applied research
(Canﬁeld and Fisher, 2001). The better the crystal quality the
more likely it will produce a satisfactory outcome for further
study (Hartshorne and Stuart, 1964). The high quality of a sin-
gle crystal is crucial for determination of the crystal structure
of any compound resulting in thorough understanding of crys-
tal stability and molecular interaction.
2. Experiment section
2.1. Materials and instruments
Sildenaﬁl citrate (Lot no. SCVIID1209040) was obtained from
Smilax Laboratories Limited (Andhra Pradesh, India). All
starting chemical reagents were analytical grade obtained from
RCI Labscan (Bangkok, Thailand). Absolute ethanol was
from Merck (Darmstadt, Germany). Melting points were mea-
sured on a Bu¨chi melting point B-540 apparatus (Switzerland).
Infrared spectra were recorded by using FT-IR spectropho-
tometer (Perkin Elmer Inc., Hercules, CA, USA). 1H NMR
was analyzed using a Fourier transform 500 MHz NMR spec-
trometer (Unity Inova; Varian, Darmstadt, Germany). The
single crystals were analyzed using the X-ray diffractometer
(model X8APEX with detector APEX II, Bruker, Germany).
The collection of the X-ray diffraction data was performed
on a SMART Bruker 1000 CCD area-detector diffractometer
(SMART version 5.618, 2002).
2.2. Crystallization experimental processes
The sildenaﬁl and sildenaﬁl citrate were crystallized by using
typical solvents for growing single crystals of organic com-
pounds. The solvents used were: water (H2O), absolute ethanol
(CH3CH2OH), methanol (CH3OH), isopropanol ((CH3)2CHOH),
dichloromethane (CH2Cl2), ethyl acetate (CH3CO2C2H5),
acetone (CH3(CO)CH3), toluene (C6H5CH3), benzene (C6H6),
acetonitrile (CH3CN) and hexane (C6H14).
Sildenaﬁl citrate (10 g, 15 mmol) was added to 100 mL of
these solvents or solvent mixtures in various ratios. The solu-
tion was ﬁltered, stored at room temperature and protected
from light. The crystallization methods were optimized by
the following methods.
2.2.1. Thermal effects
The methods to obtain growth of crystals were performed in a
cold room (2–8 C), room temperature (25–30 C) and in a hot
condition (70–80 C).
2.2.2. Stirring process
The crystallization techniques used both stirring with a mag-
netic stirrer and non-stirring to optimize the crystal growth.
2.2.3. pH
The pH of the water or water mixture was adjusted with either
1 M HCl or 1 M NaOH.
2.2.4. Crystallization technique
Three different methods were used for the crystallization pro-
cess (Fig. 2) including: (1) Solution crystallization: a saturatedsolution of sildenaﬁl citrate was obtained in different solvents
or solvent mixtures and stored for crystallization. (2) Antisol-
vent addition: an antisolvent was added slowly to a saturated
solution of sildenaﬁl citrate dissolved in various solvents and
crystal growth was observed. (3) Reﬂux: sildenaﬁl citrate was
heated in a ﬂask ﬁtted with a condenser to produce a hot sat-
urated solution which was then allowed to cool to room tem-
perature to force precipitation. (4) Slow solvent evaporation: a
saturated solution of sildenaﬁl citrate was obtained in different
solvents or solvent mixtures for crystallization by heat at tem-
perature not exceeding 60 C.
2.3. Infrared spectroscopy
A small amount of sample was sealed into KBr pellets by a
hydraulic press prior to measurement of the IR spectrum at
ambient temperature. The functional groups of sildenaﬁl and
sildenaﬁl citrate monohydrate were recorded in the frequency
range of 4000–400 cm1.
2.4. 1H NMR spectroscopy
Compounds (1) and (2) were dissolved in D2O and magneti-
cally stirred for 4–6 h at ambient temperature to obtain solu-
tions. The characteristics of the 1H-NMR chemical shifts of
(1) and (2) were recorded.
2.5. X-ray crystallography data of compounds (1) and (2)
A colorless plate crystal of (1) and colorless needle crystal of
(2) were mounted on a glass ﬁber. X-ray data were collected
on a SMART Bruker 1000 CCD area-detector diffractometer
equipped with a graphite-monochromated Mo Ka radiation
(k= 0.71073 A˚) at 298 K. A full sphere of data was
obtained for each, using the omega scan method. The detector
frames were integrated by the use of the program SAINT
Table 1 Full list of experimental conditions and results.
Reaction No. Experimental conditions Product obtained
1 Acetone, RT, stir, sc No crystal observed
2 Acetone, RT, stir, water, aa No crystal observed
3 Acetone, RT, stir, water, aa No crystal observed
4 Acetonitrile, RT, stir, sc No crystal observed
5 Acetonitrile, RT, stir, water, aa No crystal observed
6 Benzene, RT, stir, sc No crystal observed
7 Benzene, RT, stir, water, aa No crystal observed
8 Dichloroethane, RT, stir, sc No crystal observed
9 Dichloroethane, RT, stir, water, aa No crystal observed
10 Ethyl acetate, RT, stir, sc No crystal observed
11 Ethyl acetate, RT, stir, water, aa No crystal observed
12 Hexane, RT, stir, sc No crystal observed
13 Hexane, RT, stir, water, aa No crystal observed
14/15 Isopropanol, RT, stir, sc/se No crystal observed
16 Isopropanol, RT, stir, water, aa No crystal observed
17/18 Toluene, RT, stir, sc/se No crystal observed
19 Toluene, RT, stir, water, aa No crystal observed
20/21 Ethanol, RT, stir, sc/se Sildenaﬁl citrate monohydrate
22 Ethanol, hot, stir, sc Sildenaﬁl citrate monohydrate
23 Methanol, RT, acid, sc Sildenaﬁl citrate monohydrate
24 Methanol, RT, sc Sildenaﬁl citrate monohydrate
25/26 Methanol, RT, stir, sc/se Sildenaﬁl citrate monohydrate
27 Methanol:ethanol (1:1), RT, stir, sc Sildenaﬁl citrate monohydrate
28 Water:ethanol (1:1), RT, sc Sildenaﬁl citrate monohydrate
29 Water, hot, acid, sc Sildenaﬁl citrate monohydrate
30 Water, hot, rf Sildenaﬁl citrate monohydrate
31 Water, methanol (1:1), hot, stir, sc Sildenaﬁl citrate monohydrate
32 Water:ethanol (1:1), hot, sc Sildenaﬁl citrate monohydrate
33/34 Water:ethanol (18:7), acid, RT, sc/se Sildenaﬁl citrate monohydrate
35 Water:ethanol (1:1), acid, RT, sc Sildenaﬁl citrate monohydrate
36 Water:ethanol (1:1), base, hot, stir, sc Sildenaﬁl citrate monohydrate
37 Water:ethanol (1:1), hot, stir, sc Sildenaﬁl citrate monohydrate
38/39 Water:methanol (1:1), hot, stir, sc/se Sildenaﬁl citrate monohydrate
a40 Water:methanol (1:1), RT, stir, sc Sildenaﬁl citrate monohydrate
a41 Water, neutral, cold, stir, sc Sildenaﬁl
42/43 Water, acid, cold, sc/se Sildenaﬁl
44 Water, acid, RT, sc Sildenaﬁl
45 Water, base, RT, sc Sildenaﬁl
46/47 Water, neutral, cold, stir, sc/se Sildenaﬁl
48 Water:ethanol, cold, sc Sildenaﬁl
49/50 Water:methanol (1:1), cold, sc/se Sildenaﬁl
sc = solution crystallization process, aa = antisolvent addition process, rf = reﬂux process.
se = slow solvent evaporation.
a Crystals obtained from this reaction were used for analysis by X-ray diffractometer.
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rected for absorption by Gaussian integration using the SAD-
ABS program (Sheldrick, Version 2.03a, 2001). The solution
structure was carried out using direct methods.
Space groups P21/c and Pbca were selected for (1) and (2)
respectively, and conﬁrmed by the subsequent structural anal-
ysis. The ADDSYM option in PLATON revealed no addi-
tional symmetry (Spek, PLATON, Version June 2002, 2002).
A full-matrix least-squares reﬁnement on F2 (including all
data) was performed using the SHELXTL program
(Sheldrick, Version 6.12, 2001). All non-hydrogen atoms were
reﬁned with anisotropic thermal parameters. All hydrogen
atom positions, except on the O12 of compound (2), were
located from different Fourier maps but were constrained to
ideal geometries using a ‘riding’ model. The oxygen O12 atomin the compound (2) seemed to be disordered and difﬁcult to
ﬁx. Because of the high R value and distorted geometry of
the hydrate, hydrogen atoms could not be found and were
omitted for the reﬁnement. All packing diagrams and thermal
ellipsoid plots were produced using the Diamond software pro-
gram (Brandenburg and Putz, 2005).
3. Results and discussion
3.1. Crystals obtained from various techniques
Table 1 shows the full experimental results from the crystalli-
zation process. Sildenaﬁl does not crystallize from an organic
solvent that is immiscible with water (reactions 1–19). The
estimations of the pKa value for sildenaﬁl varied. The most
Figure 3 Photograph of crystals of sildenaﬁl (1) and sildenaﬁl citrate monohydrate (2).
Figure 4 The IR spectrum of sildenaﬁl (1) and sildenaﬁl citrate
monohydrate (2).
Figure 5 The molecular structure of (1) showing the crystallo-
graphic numbering scheme with ellipsoids drawn at the 30%
probability.
508 S. Sawatdee et al.reliable pKa1 was 9.84 for the amide (pyrimidine ring) and the
pKa2 was 7.10 at the tertiary amine (piperazine ring) (Al-Omari
et al., 2006). It was of interest, that various solvents for the
crystallization of sildenaﬁl had important effects on the growth
of crystals. When the polar solvent was chosen such as
hydroalcohol to dissolve sildenaﬁl citrate, it caused the crystal-
lization. It was to conﬁrm that the polarity of solvent affected
the growth of sildenaﬁl crystal.
When the polarity of the solvent was less than 0.6 there was
no crystal growth. However, when the polarity of the solvent
was higher than 0.6 such as ethanol (0.654), methanol
(0.762) or water (0.822) crystal growth from a mixed solvent
for both (1) and (2) did occur (Reichardt, 2003). The growth
of crystals of (1) or (2) depended on the temperature of the
crystallization process. Table 1 shows the crystal growth of sil-
denaﬁl and sildenaﬁl citrate monohydrate in various experi-
ments. The effects of pH on the pKa of sildenaﬁl were
performed by adjusting pH to be neutral, acidic or basic con-
ditions. Crystal growth of (1) at neutral, acidic or basic solu-
tions in the hydroalcoholic solutions produced crystals of
sildenaﬁl at a cold temperature. It is important to note that
at room temperature, sildenaﬁl in either an acidic or basic con-
ditions was induced to grow crystals. In contrast to a previousreport by Stepanovs and Mishnev (2012), they prepared silde-
naﬁl crystals by reacting with KOH in acetone using a slow
evaporation of the solvent at room temperature. This process
was more complicated than our process. Sildenaﬁl was ﬁrst dis-
solved in hydroalcoholic and then stored in a refrigerator to
obtain sildenaﬁl growth. In addition, our work showed that
acetone was not a suitable solvent for sildenaﬁl crystal growth
because sildenaﬁl did not dissolve in acetone.
The reactions 41–50 were suitable to obtain crystals for (1).
This process is very simple and less toxic as it used the hydro-
alcoholic solvent. The best reaction to obtain perfect crystals
of (1) is 41. By following this procedure, the crystals were pro-
duced easily within 1 day. If the reaction was left longer, per-
fect single crystals for X-ray crystallography were obtained
with a yield ranging from 20% to 30%. The selected crystal
used for X-ray crystallography was from reaction S1 as shown
in Fig. 3.
Crystals of (2) were prepared from the hydroalcoholic sol-
vent. This crystallization process generated crystals more easily
because the starting material was sildenaﬁl citrate. The
Figure 6 The molecular structure of (2) showing the crystallo-
graphic numbering scheme with ellipsoids drawn at the 30%
probability.
Sildenaﬁl and sildenaﬁl citrate monohydrate crystals 509addition of an antisolvent showed no crystal growth because
sildenaﬁl was likely to dissolve in the hydroalcoholic solution
and precipitated prior to crystal growth.
The method of crystallization such as solution crystalliza-
tion, slow solvent evaporation also had an effect on the crystal
growth. Ethanol, methanol, water or mixture of hydroalco-
holic compounds inﬂuenced the quality of the crystal. TheTable 2 Crystallographic data of compounds (1) and (2).
Compound (1)
Empirical formula C22H30N6O4S
Formula weight 474.58
Wavelength (A˚) 0.71073
Crystal system Monoclinic
Space group P21/c
a (A˚) 17.3380(15)
b (A˚) 16.9739(11)
c (A˚) 7.9847(6)
a () 90.00
b () 99.824(4)
c () 90.00
Volume (A˚3) 2315.4(3)
Z 4
Density (calculated) (g cm3) 1.362
Absorption coeﬃcient (mm1) 0.182
F(000) 1012
Crystal size (mm3) 0.34 · 0.22 · 0.20
h range for data collection () 1.19–25.16
Index ranges 20 6 h 6 18, 20 6 k 6
Reﬂections collected 10868
Independent reﬂections 4065 [Rint = 0.0325]
Completeness to h= 22.50 97.6%
Absorption correction None
Max and min transmission 0.964 and 0.953
Reﬁnement method Full-matrix least-squares o
Data/restraints/parameters 4167/0/298
Goodness-of-ﬁt on F2 1.077
Final R indices [I> 2r(I)] R1 = 0.0448, wR2 = 0.129
R indices (all data) R1 = 0.0643, wR2 = 0.150
Largest diﬀ. peak and hole (e A˚3) 0.608 and 0.758use of ethanol or the hydroalcoholic solvents (ethanol or meth-
anol) generated sildenaﬁl citrate monohydrate crystals within
2 weeks. Changing the temperature (cold, room temperature
or heat) had little effect on the crystal growth. A sildenaﬁl crys-
tal was formed in a cold process only from a hydroalcoholic
condition. The citrate molecule was extracted from the sildena-
ﬁl molecules. Any transfer of electrons from the salt form may
cease after the temperature was reduced. The crystallization
processes were not crucial for producing sildenaﬁl crystals,
but the time for crystallization was a prime factor. Sildenaﬁl
citrate monohydrate was obtained immediately after reﬂuxing.
Slow solvent evaporation and solution crystallization were a
time consuming process for crystal growth. The crystal growth
in this way did not occur because sildenaﬁl was likely to dis-
solve in the hydroalcoholic solution.
The reactions 20–40 produced crystals of (2). Hydroalco-
holic solvents gave better crystals than dimethylformamide
(Yathirajan et al., 2005). These processes with the crystalliza-
tion from solution techniques took a shorter time. Fig. 3 shows
crystals of (2) obtained from the reaction 40 that were used for
X-ray crystallography. The percent yield of (2) from reactions
20–40 varied from 25% to 35%.
3.2. Infrared spectroscopy
The infrared spectra of (1) and (2) were very similar as
expected from the similarity of their structural formulas
(Fig. 4). For both compounds, the IR bands at aroundCompound (2)
C28H40N6O12S
684.72
0.71073
Orthorhombic
Pbca
24.0800(16)
11.0160(7)
24.5877(17)
90.00
90.00
90.00
6522.3(8)
8
1.395
0.170
2896
74.00 · 0.617 · 0.00
1.66–22.50
20, 9 6 l 6 9 25 6 h 6 25, 11 6 k 6 11, 26 6 l 6 26
53226
4252 [Rint = 0.0775]
100.0%
None
0.998 and 0.882
n F2 Full-matrix least-squares on F2
4252/0/425
1.124
6 R1 = 0.0757, wR2= 0.1805
0 R1 = 0.0889, wR2= 0.1892
0.598 and 0.461
Table 3 Selected bond lengths [A˚] and angles [] for (1) and (2).
Compound (1) Compound (2)
S(1)AO(1) 1.4299(18) S(1)AO(1) 1.425(4)
S(1)AO(2) 1.4306(19) S(1)AO(2) 1.419(4)
S(1)AN(1) 1.637(2) S(1)AN(1) 1.632(4)
S(1)AC(6) 1.764(3) S(1)AC(6) 1.765(5)
O(3)AC(14) 1.358(3) O(3)AC(14) 1.349(6)
O(4)AC(13) 1.225(3) O(4)AC(13) 1.217(6)
N(1)AC(1) 1.479(3) N(1)AC(1) 1.473(6)
N(5)AN(6) 1.350(3) N(5)AN(6) 1.347(6)
N(4)AC(10) 1.376(3) O(5)AC(23) 1.201(8)
O(8)AC(28) 1.243(5)
O(9)AC(28) 1.242(5)
N(2)AC(2) 1.488(6)
N(2)AC(3) 1.499(6)
N(2)AC(5) 1.486(3)
O(1)AS(1)AO(2) 120.10(11) O(2)AS(1)AO(1) 120.1(3)
O(1)AS(1)AN(1) 107.17(10) O(2)AS(1)AN(1) 107.1(2)
O(2)AS(1)AC(6) 108.24(11) O(1)AS(1)AN(1) 106.2(2)
C(14)AO(3)AC(17) 119.19(18) N(1)AS(1)AC(6) 105.8(2)
C(1)AN(1)AC(4) 112.7(2) C(14)AO(3)AC(17) 121.8(4)
C(9)AN(3)AC(13) 126.3(2) C(4)AN(1)AS(1) 116.0(3)
N(6)AN(5)AC(12) 111.25(19) C(2)AN(2)AC(5) 111.1(4)
N(1)AC(4)AC(3) 109.9(2) N(5)AN(6)AC(12) 110.8(4)
C(7)AC(6)AC(16) 120.4(2) N(5)AN(6)AC(22) 120.7(5)
N(4)AC(9)AN(3) 122.9(2) O(8)AC(28)AO(9) 127.2(4)
O(4)AC(13)AN(3) 121.0(2) O(8)AC(28)AC(25) 116.1(4)
O(3)AC(17)AC(18) 106.7(2) O(5)AC(23)AC(24) 124.3(6)
C(11)AC(19)AC(20) 116.3(2) O(6)AC(23)AC(24) 118.1(5)
C(19)AC(20)AC(21) 111.7(2) O(11)AC(27)AC(26) 118.4(5)
O(1)AS(1)AN(1)AC(1) 47.31(19) O(1)AS(1)AN(1)AC(4) 45.3(4)
O(2)AS(1)AN(1)AC(1) 177.38(16) O(2)AS(1)AN(1)AC(4) 174.9(3)
C(6)AS(1)AN(1)AC(1) 67.10(19) C(6)AS(1)AN(1)AC(4) 70.0(3)
C(12)AN(5)AN(6)AC(11) 0.2(3) C(11)AN(5)AN(6)AC(12) 0.3(6)
C(22)AN(5)AN(6)AC(11) 178.1(2) S(1)AN(1)AC(1)AC(2) 163.5(3)
C(4)AN(1)AC(1)AC(2) 52.8(3) C(3)AN(2)AC(2)AC(1) 57.2(5)
O(2)AS(1)AC(6)AC(7) 30.7(2) O(1)AS(1)AC(6)AC(16) 33.3(5)
C(16)AC(6)AC(7)AC(8) 0.9(4) C(16)AC(6)AC(7)AC(8) 0.0(7)
C(6)AC(7)AC(8)AC(14) 0.4(3) C(6)AC(7)AC(8)AC(14) 0.4(7)
C(10)AN(4)AC(9)AN(3) 1.6(3) C(10)AN(4)AC(9)AN(3) 1.8(6)
C(9)AN(4)AC(10)AC(12) 0.2(3) C(9)AN(3)AC(13)AC(12) 0.6(7)
N(5)AN(6)AC(11)AC(10) 0.3(3) N(4)AC(10)AC(11)AC(19) 1.0(9)
N(6)AN(5)AC(12)AC(10) 0.0(3) N(5)AN(6)AC(12)AC(10) 0.1(6)
C(23)AC(24)AC(25)AC(26) 178.6(4)
O(7)AC(25)AC(26)AC(27) 56.7(5)
510 S. Sawatdee et al.3300 cm1 were assigned to the secondary amides (NAH
stretching) vibrations. The NAH bending vibrations were
observed in the regions of 1650–1580 cm1. The ‚CAH
stretching in an aromatic ring was observed at 3100–
3000 cm1 which was at a slightly higher frequency than those
for ACAH stretchings in the alkanes that were around 3000–
2900 cm1. The IR characteristics of these compounds corre-
sponded with a previous report (Yathirajan et al., 2005).
Another characteristic band was a strong intensity around
1703 cm1 that was attributed to the C‚O. The aromatic
hydrocarbons showed absorption bands in the regions of
1600–1585 cm1 and 1500–1400 cm1 due to carbon–carbon
stretching vibrations in the aromatic rings. An asymmetric
stretch of the S‚O occurred at 1359 cm1 and there was a
symmetrical stretching at 1172 cm1. The medium intensity
characteristic for the CAN stretching modes occurred around
1300–1000 cm1 that overlapped with the aromatic amines andsulfones. The weak bands observed at wave numbers of 1200–
1000 cm1 in all spectra were assigned to in-plane CAH
deformations.
The dominant band that appeared in the higher region of
3612 cm1 clearly conﬁrmed the OAH stretching of the
hydrated form in (2) (Pavia et al., 2001). In addition the broad
bands that appeared in the lower regions of 3411 cm1 were for
the OAH stretching of the citrate moiety (Pavia et al., 2001).
The reasons for the OAH stretching of carboxylic acids being
so broad were due to the carboxylic acids presenting as hydro-
gen-bonded dimers which was in an agreement with their X-ray
crystallography structures, as can be seen in Figs. 5 and 6.
3.3. 1H NMR spectroscopy
1H NMR of (1) (D2O, ppm) d: C1 3.307 (ACH2, broad s, 2H),
C2 3.725 (ACH2, broad s, 2H), C3 3.618 (ACH2, broad s, 2H),
Table 4 Comparison of hydrogen bondings between this work and related structure (A˚ and ).
Compound DAH  A d(DAH) d(H  A) d(D  A) <(DHA) Symmetry
(1) N3AH3A   O3 0.860 1.950 2.640 136.35
C1AH1C   O1 0.930 1.630 2.499 146.90
C22AH22B  O2 0.960 1.640 2.513 138.40
(2) N3AH3A   O3 0.860 1.945 2.614 133.74
C1AH1C   O1 0.970 1.642 2.462 130.50
C2AH2B   O4 0.970 1.570 2.317 154.30
O6AH6   O8 0.820 2.541 3.180 135.81
O7AH7   O8 0.820 1.801 2.620 176.05 Ax+ 1/2, y  1/2, z
O9AH9   O11 0.820 1.754 2.505 151.35 x+ 1/2, y+ 1/2, z
O11AH11   O9 0.820 1.791 2.505 144.61 x+ 1/2, y  1/2, z
O6AH6   O9 0.820 2.321 3.130 169.09
O10AH12A  O12 1.221 1.738 2.732 134.09
(1) (Ref. Stepanovs and Mishnev (2012) N3AH3A  O4 0.880 1.940 2.622 134.00
(2) (Ref. Yathirajan et al. (2005) N14AH14  O3 0.930 1.880 2.764 (6) 159.00
N14AH14  O62 0.930 2.300 2.911 (6) 123.00
N32AH32  O27 0.880 1.940 2.622 (6) 134.00
O12AH12  O38 0.840 1.980 2.771 (7) 157.00 1  x, 2  y, 1  z
O3AH3  O61 0.840 1.770 2.605 (5) 173.00 3/2  x, y  1/2, z
O52AH52  O62 0.840 1.730 2.490 (6) 149.00 3/2  x, y  1/2, z
O1WAH1WA  O1 0.840 2.110 2.946 (13) 179.00 1/2 + x, y, 1/2  z
O1WAH1WB  O51 0.840 1.840 2.678 (16) 179.00
Sildenaﬁl and sildenaﬁl citrate monohydrate crystals 511C4 3.294 (ACH2, broad s, 2H), C5 2.928 (ACH3, s, 3H), C7
8.176 (ACH, d, 1H), C15 7.375 (ACH, d, 1H), C16 7.907
(ACH, dd, 1H), C17 4.803 (ACH2, q, 2H), C18 1.463
(ACH3, t, 3H), C19 2.557 (ACH2, t, 2H), C20 1.816 (ACH2,
sext, 2H), C21 0.991 (ACH3, t, 3H), C22 4.307 (ACH3, s,
3H), ANH 12.230 (ring B, s, 1H).
The 1H NMR of (2) (D2O) d was very similar with (1) and
the exception was that the d of the citrate salts showed at
2.672 ppm (-CH2 of citrate). The downﬁeld region of ACOOH
was shown at 11–12 ppm.
3.4. Crystallographic structures
The detailed crystallographic data of compounds (1) and (2)
are listed in Table 2. Selected bond lengths, angles and torsionFigure 7 The packing scheme along the c-axis for sildenaﬁl (1). Diffeangles are listed in Table 3. Table 4 shows a comparison of
hydrogen bonding obtained in this work and those obtained
from previous structures (Stepanovs and Mishnev, 2012;
Yathirajan et al., 2005).
The crystal structure of (1) presented as a monoclinic space
group P21/c which consisted of a molecule of sildenaﬁl
(C22H30N6O4S) containing 4 rings: pyrimidine (A), pyrazole
(B), phenyl (C), and piperazine (D) rings, (Fig. 5). The
geometrical rings A, B and C are essentially planar as seen
in the previous report (Stepanovs and Mishnev, 2012). Ring
D is a typical chair conformation with torsion angles of
N(1)AC(1)AC(2)AN(2) that is 57.1(3) as shown in Table 3.
The Pbca orthorhombic crystal structure of (2) consisted of
the sildenaﬁl (C22H30N6O4S) moiety, citrate (C6H7O7) and
water (H2O) as shown in Fig. 6. This structure was differentrences in the symmetry operations are clearly indicated by colors.
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containing a sildenaﬁl cation (C22H31N6O4S)
+ moiety, a cit-
rate anion (C6H7O7)
 and water (H2O) (Yathirajan et al.,
2005). The main difference was the hydrogen atom around
the N2 of piperazine (D) ring and the hydrogen atom of the
carboxyl group in the citrate moiety. It is a fact that for the
bond and angle parameters, there was no hydrogen atom
around the N2 of the piperazine (D) ring. This was indicated
by the delocalized CAN bonds of 1.487, 1.488 and 1.501 A˚.
As far as the bond lengths and angles around the C6 of the cit-
rate moiety are concerned, this group is the carboxylic group.
The structural comparisons of (1) were not different from
the sildenaﬁl moiety of (2). Although all the bond lengths
and bond angles in the sildenaﬁl molecules from both com-
pounds were in the normal range, the average bond lengths
and bond angle parameter of (1) were slightly greater than
(2). This may result from the greater stability of (1) compared
to (2) because of the disordered oxygen of the hydrate in (2).
However, these parameters were also in good agreement with
those found in the previously reported structures (Stepanovs
and Mishnev, 2012; Yathirajan et al., 2005). The S‚O,
C(13)‚O and N‚N bond length of the sildenaﬁl moieties
from (1) and (2) strongly indicated that they were double bond
characters as listed in Table 3. The citrate moiety
parameters were also in the normal range which is
C(23)AC(24)‚C(25)‚C(26) and was 178.6(4) and the
C‚O bond parameters were about 1.201(8)–1.243(6)A˚.
The crystal packing of compounds (1) and (2) contained 4
and 8 molecules in a unit cell (Figs. 7 and 8, respectively).
The symmetry operations are clearly illustrated by different
colors.
When packing, the most intriguing features arose from the
weak interactions at supramolecular level as shown in Figs. 8Figure 8 The packing scheme along the c-axis for sildenaﬁl citrate m
indicated by colors.and 9. The inter- and intra-molecular interactions are listed
in Table 4.
In both compounds (1) and (2), the typical intramolecular
hydrogen bond was generated by the NAH  O bond. The
N3AH3A  O3 of 2.640 A˚ of (1) was slightly greater than those
in the former reported molecules Stepanovs and Mishnev,
2012; Yathirajan et al., 2005) (Table 4). This may be caused
by the crystal quality and stability of this work over the
previous report and was conﬁrmed by the lower R-factors
(0.0448 vs 0.069 for compound (1) and 0.0757 vs 0.098 for
compound (2)).
Moreover, a survey of the weak intermolecular interactions
in the solid state structure revealed a few short intermolecular
CAH  O interaction in the crystal structures of (1) and (2),
which can be characterized by weak hydrogen bonds from
electrostatic or mostly electrostatic interactions (Gilli, 2002).
In the crystal structures of (1), the oxygen atoms of the sul-
fonyl group play a key role in the generation of the intermolec-
ular interactions. A hydrogen atom of the methyl group of ring
A generated the weak interaction with an oxygen atom of the
sulfonyl group (C22AH22b  O2) of 2.513 A˚, forming an
inﬁnite 1-D layer. The carbonyl oxygen atom of the phenyl
ring B connects with the hydrogen atoms of ring A via
C15AH15A  O4 (2.391 A˚) as seen in Fig. 9.
In the crystal structures of (2), a hydrogen atom of the
methyl group generated the weak interaction with an oxygen
atom of the sulfonyl group (C1AH1  O1) of 2.462 A˚, forming
an inﬁnite 1-D zigzag chain along the b axis as seen in the pre-
vious report (Yathirajan et al., 2005). Furthermore, this 1-D
supramolecular chain was interconnected with a carbonyl
group via C2AH2B  O4 (2.317 A˚) into a 2-D supramolecular
network along the c axis as seen in Fig. 10. As far as the citrate
and water moieties are concerned, the weak interaction of (2)onohydrate (2). Differences in the symmetry operations are clearly
Figure 9 The only intermolecular interactions of compound (1)
are shown as broken lines. Some hydrogen atoms have been
omitted for clarity.
Figure 10 The only intermolecular interactions of the sildenaﬁl
molecule of compound (2) plotted along the a axis. Some
hydrogen atoms have been omitted for clarity. Hydrogen bonds
are shown as broken lines.
Sildenaﬁl and sildenaﬁl citrate monohydrate crystals 513was quite complicated, because of the disordered hydrated
oxygen atoms. This disordered oxygen atom affected not only
the hydrogen atom location but also other weak interactions.
Besides that, it could form various hydrogen bonds with OÆÆÆO
distances of 2.505–3.180 A˚ (see Table 4). However, all these
supramolecular interactions in the solid state may presumably
stabilize the crystal structures.
4. Conclusions
The crystallization of sildenaﬁl citrate obtained 2 types of
sildenaﬁl which are sildenaﬁl base and sildenaﬁl citrate
monohydrate. The process of crystallization is an important
factor on the crystal growth. The polar solvent is suitable for
sildenaﬁl crystal growth. The cool temperature showed the
sildenaﬁl base crystal may be able to grow in acid or basic
conditions. The sildenaﬁl citrate monohydrate was easy to
crystallize by various techniques. The stability of sildenaﬁl
crystal was affected by bond length, bond angle and intramo-
lecular interaction.Acknowledgments
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